The Q2 revenue decline from $3.9M to $1.7M reflects expected channel fill normalization, but the $19.7M CMO cancellation charge and $2.6M pre-financing cash position highlight severe capital constraints. The post-quarter $36.5M financing and Jefferies strategic review suggest a potential sale or partnership is being actively explored. Watch for updates on new BDS supplier agreements and formulary conversion rates as key leading indicators of commercial traction.
Price Chart
Executive Summary
Citius Oncology reported fiscal Q2 2026 (March 31, 2026) net product revenue of $1.7M, down from $3.9M in Q1 due to initial channel fill normalization, with 80% gross margins. The company secured up to $36.5M in post-quarter debt/equity financing (including $10M term loan funded and ~$11.5M warrant exercises) but posted a net loss of $26.6M driven by a $19.7M one-time CMO contract cancellation charge. Cash stood at $2.6M pre-financing, with runway extended only through November 2026, and Jefferies retained to evaluate strategic alternatives.
Key Financial Metrics
Key Facts
- Q2 FY2026 net product revenue of $1.7M (vs $0 in prior-year period); Q1 was $3.9M reflecting initial distributor channel fill
- Gross margin of 80% on product revenue; $4.5M gross profit on $5.6M H1 revenue
- Net loss of $26.6M for Q2, vs $7.7M in prior-year period, driven by $19.7M one-time CMO contract cancellation charge
- Cash and cash equivalents of $2.6M as of March 31, 2026, before post-quarter financings
- Secured up to $36.5M post-quarter: $10M funded term loan from Avenue Capital (up to $25M total) and ~$11.5M from warrant exercises
- 83% of target accounts on formulary or in review; near 100% payer coverage with no reimbursement denials
- Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives
- Expects combined Citius Oncology and Citius Pharma funds to sustain operations only through November 2026
- Initiated first European shipment via Named Patient Programs across 19 markets
- Positive topline Phase 1 combo data for LYMPHIR with pembrolizumab and pre-CAR-T in DLBCL
Financial Impact
Q2 revenue $1.7M (down 56% QoQ from $3.9M in Q1 due to channel fill normalization); net loss $26.6M including $19.7M one-time charge; post-quarter financing of up to $36.5M provides runway only through Nov 2026
Risk Factors
- Cash runway only through November 2026 even after $36.5M financing — substantial additional capital needed
- Q2 revenue decline from Q1 suggests slower-than-expected demand conversion from channel fill to treatment-driven reorders
- $19.7M CMO cancellation charge signals supply chain disruption risk during commercial ramp
- Dilution from warrant exercises and potential future equity raises; shares outstanding increased from 83.5M to 93.0M since September 2025
- Nasdaq continued listing compliance risk flagged in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-057883 |
| Document: ea0291035-8k_citius.htm | 0001213900-26-057883 |
| Document: 0001213900-26-057883-index-headers.html | 0001213900-26-057883 |
| Document: 0001213900-26-057883-index.html | 0001213900-26-057883 |
| Document: 0001213900-26-057883.txt | 0001213900-26-057883 |
| 8-K Data (Synthetic) | 0001213900-26-057883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.6000 | awaiting T+5 | — | $0.5957 (−0.72%) |
Oct 26, 2026 today | Press Release | $0.6072 | awaiting T+5 | — | $0.5957 (−1.89%) |
Oct 23, 2026 3d ago | 8-K | $0.5795 | awaiting T+5 | — | $0.5957 (−2.80%) |
Aug 12, 2026 10w ago | 8-K | $0.8115 $0.7525 | ▼ −7.27% | ▼ −6.83% | $0.5957 (−26.59%) |
Aug 5, 2026 11w ago | 8-K | $0.7850 $0.8115 | ▲ +3.38% | ▲ +3.03% | $0.5957 (−24.11%) |
Jun 8, 2026 20w ago | EFFECT | $0.7999 $0.6802 | ▲ +14.96% | ▲ +17.08% | $0.5957 (+25.53%) |
Jun 1, 2026 21w ago | 8-K | $0.7830 $0.7200 | ▼ −8.05% | ▼ −5.08% | $0.5957 (−23.92%) |
May 29, 2026 21w ago | S-3 | $0.7920 $0.7800 | ▲ +1.52% | ▼ −1.24% | $0.5957 (+24.79%) |
May 15, 2026 23w ago | 8-K | $0.8290 $0.8600 | ▲ +3.74% | ▲ +2.12% | $0.5957 (−28.14%) |
Mar 3, 2026 33w ago | EFFECT | $1.06 $1.01 | ▼ −5.19% | ▼ −4.71% | $0.5957 (−43.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers